ArticlePharmacology research & perspectives2022

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?

Lauren Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.